An LDH inhibitor (GSK 2837808A, potently inhibiting both LDHA and LDHB) abrogated the increase in cytokine production in the presence of lactate (Figures 5C and S5G–S5J), indicating an active lactate-to-pyruvate enzymatic conversion activity in this tumor-like metabolic environment. This evidence concerns the gene LDHA and neoplasm.